Literature DB >> 32134744

Minimal PD-1 expression in mouse and human NK cells under diverse conditions.

Sean J Judge1, Cordelia Dunai2, Ethan G Aguilar2, Sarah C Vick3, Ian R Sturgill2, Lam T Khuat2, Kevin M Stoffel2, Jonathan Van Dyke4, Dan L Longo5, Morgan A Darrow6, Stephen K Anderson7, Bruce R Blazar8,9, Arta M Monjazeb10, Jonathan S Serody11,12, Robert J Canter1, William J Murphy2,13.   

Abstract

PD-1 expression is a hallmark of both early antigen-specific T cell activation and later chronic stimulation, suggesting key roles in both naive T cell priming and memory T cell responses. Although significant similarities exist between T cells and NK cells, there are critical differences in their biology and functions reflecting their respective adaptive and innate immune effector functions. Expression of PD-1 on NK cells is controversial despite rapid incorporation into clinical cancer trials. Our objective was to stringently and comprehensively assess expression of PD-1 on both mouse and human NK cells under multiple conditions and using a variety of readouts. We evaluated NK cells from primary human tumor samples, after ex vivo culturing, and from multiple mouse tumor and viral models using flow cytometry, quantitative reverse-transcriptase PCR (qRT-PCR), and RNA-Seq for PD-1 expression. We demonstrate that, under multiple conditions, human and mouse NK cells consistently lack PD-1 expression despite the marked upregulation of other activation/regulatory markers, such as TIGIT. This was in marked contrast to T cells, which were far more prominent within all tumors and expressed PD-1. These data have important implications when attempting to discern NK from T cell effects and to determine whether PD-1 targeting can be expected to have direct effects on NK cell functions.

Entities:  

Keywords:  Immunology; Immunotherapy; NK cells

Mesh:

Substances:

Year:  2020        PMID: 32134744      PMCID: PMC7260004          DOI: 10.1172/JCI133353

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  69 in total

1.  NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells.

Authors:  M K Slifka; R R Pagarigan; J L Whitton
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

Review 2.  Regulation of the natural killer cell receptor repertoire.

Authors:  D H Raulet; R E Vance; C W McMahon
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells.

Authors:  Emilie Narni-Mancinelli; Eric Vivier; Yann M Kerdiles
Journal:  Int Immunol       Date:  2011-06-10       Impact factor: 4.823

4.  Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

Authors:  Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2014-02-11       Impact factor: 11.151

5.  The head and neck cancer immune landscape and its immunotherapeutic implications.

Authors:  Rajarsi Mandal; Yasin Şenbabaoğlu; Alexis Desrichard; Jonathan J Havel; Martin G Dalin; Nadeem Riaz; Ken-Wing Lee; Ian Ganly; A Ari Hakimi; Timothy A Chan; Luc Gt Morris
Journal:  JCI Insight       Date:  2016-10-20

6.  Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis.

Authors:  Jing Zhou; Hui Peng; Kun Li; Kun Qu; Baohui Wang; Yuzhang Wu; Lilin Ye; Zhongjun Dong; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

7.  Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

Authors:  J H Gong; G Maki; H G Klingemann
Journal:  Leukemia       Date:  1994-04       Impact factor: 11.528

8.  Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages.

Authors:  R H Wiltrout; A Santoni; E S Peterson; D C Knott; W R Overton; R B Herberman; H T Holden
Journal:  J Leukoc Biol       Date:  1985-05       Impact factor: 4.962

Review 9.  Targeting natural killer cells in solid tumors.

Authors:  Guillaume Habif; Adeline Crinier; Pascale André; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Cell Mol Immunol       Date:  2019-03-25       Impact factor: 11.530

10.  Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma.

Authors:  Alexander A Tong; Hasan Hashem; Saada Eid; Frederick Allen; Daniel Kingsley; Alex Y Huang
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

View more
  49 in total

Review 1.  The cancer-natural killer cell immunity cycle.

Authors:  Nicholas D Huntington; Joseph Cursons; Jai Rautela
Journal:  Nat Rev Cancer       Date:  2020-06-24       Impact factor: 60.716

Review 2.  Tumor-Infiltrating Natural Killer Cells.

Authors:  Beatriz Cózar; Marco Greppi; Sabrina Carpentier; Emilie Narni-Mancinelli; Laura Chiossone; Eric Vivier
Journal:  Cancer Discov       Date:  2020-12-04       Impact factor: 39.397

3.  Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity.

Authors:  Rosa Sottile; M Kazim Panjwani; Colleen M Lau; Anthony F Daniyan; Kento Tanaka; Juliet N Barker; Renier J Brentjens; Joseph C Sun; Jean-Benoît Le Luduec; Katharine C Hsu
Journal:  Sci Immunol       Date:  2021-09-24

4.  Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.

Authors:  Lauren E Milling; Daniel Garafola; Yash Agarwal; Shengwei Wu; Ayush Thomas; Nathan Donahue; Josetta Adams; Nikki Thai; Heikyung Suh; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2021-10-22       Impact factor: 11.151

5.  Programmed cell death protein 1 on natural killer cells: fact or fiction?

Authors:  Monica M Cho; Aicha E Quamine; Mallery R Olsen; Christian M Capitini
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

6.  Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation.

Authors:  Zachary Davis; Martin Felices; Todd Lenvik; Sujan Badal; Joshua T Walker; Peter Hinderlie; James L Riley; Daniel A Vallera; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood Adv       Date:  2021-02-23

Review 7.  Emerging concepts in PD-1 checkpoint biology.

Authors:  Kristen E Pauken; James A Torchia; Apoorvi Chaudhri; Arlene H Sharpe; Gordon J Freeman
Journal:  Semin Immunol       Date:  2021-05-15       Impact factor: 11.130

Review 8.  Unraveling exhaustion in adaptive and conventional NK cells.

Authors:  Aimee M Merino; Hansol Kim; Jeffrey S Miller; Frank Cichocki
Journal:  J Leukoc Biol       Date:  2020-07-29       Impact factor: 4.962

9.  Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth.

Authors:  Shuwei Guo; Chao Huang; Fengfeng Han; Bin Chen; Ying Ding; Yuanyuan Zhao; Zhihong Chen; Shaodi Wen; Mei Wang; Bo Shen; Wei Zhu
Journal:  Stem Cells Int       Date:  2021-06-29       Impact factor: 5.443

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.